ArticleBritish journal of haematology2026
The value of C-X-C motif chemokine ligand 9 (CXCL9) in the differential diagnosis and management of haemophagocytic lymphohistiocytosis.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To identify key cytokines for the differentiation and treatment monitoring of haemophagocytic lymphohistiocytosis (HLH). We retrospectively analysed the clinical data and cytokine profiles from 66 patients with HLH, sepsis, Kawasaki disease (KD) and infectious mononucleosis (IM). Hierarchical clustering analysis was performed among those diseases. The diagnostic value of the markers was assessed using logistic regression and receiver operating characteristic (ROC) curves. Longitudinal changes in cytokines were detected in HLH patients. Cluster analysis revealed substantial overlap in the cytokine profiles between HLH and IM, characterized by high levels of C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), interferon-gamma (IFN-γ), soluble cluster of differentiation 25 (sCD25) and interleukin-18 (IL-18). The cytokine profiles differed from sepsis and KD patients. The combined detection of CXCL9 and haemoglobin (Hb) achieved an area under the curve (AUC) of 0.943 for distinguishing Epstein-Barr virus-related HLH (EBV-HLH) from IM. CXCL9 was significantly correlated with aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) in HLH patients. Moreover, high levels of CXCL9 were associated with more severe clinical manifestations. During the monitoring of HLH cases, trends in CXCL9 and LDH levels correlated with disease progression.In conclusion, differences in cytokine profiles contribute to disease differentiation, and detection of CXCL9 holds promise for HLH diagnosis and longitudinal monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.